Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?

Othman Al-Sawaf; John F. Seymour; Arnon P. Kater; Kirsten Fischer

doi:https://doi.org/10.1016/j.hoc.2021.03.007

Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?

Othman Al-Sawaf, John F. Seymour, Arnon P. Kater, Kirsten Fischer

Research output: Contribution to journal › Review article › Academic › peer-review

7 Citations (Scopus)

Original language	English
Pages (from-to)	775-791
Number of pages	17
Journal	Hematology/oncology clinics of North America
Volume	35
Issue number	4
Early online date	2021
DOIs	https://doi.org/10.1016/j.hoc.2021.03.007
Publication status	Published - Aug 2021

Keywords

CLL
Chemoimmunotherapy
Chronic lymphocytic leukemia
Fixed-duration therapy
MRD
Minimal residual disease
Targeted agents

Access to Document

https://doi.org/10.1016/j.hoc.2021.03.007

Cite this

@article{d1f8737245ce424fb0fdeaaf020fb94b,

title = "Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?",

keywords = "CLL, Chemoimmunotherapy, Chronic lymphocytic leukemia, Fixed-duration therapy, MRD, Minimal residual disease, Targeted agents",

author = "Othman Al-Sawaf and Seymour, {John F.} and Kater, {Arnon P.} and Kirsten Fischer",

year = "2021",

month = aug,

doi = "https://doi.org/10.1016/j.hoc.2021.03.007",

language = "English",

volume = "35",

pages = "775--791",

journal = "Hematology/oncology clinics of North America",

issn = "0889-8588",